Yaohai Bio-Pharma will exhibit at CPHI Frankfurt 2025. When attending the event, connect with us at Booth 41D65 to discover end-to-end CRDMO solutions accelerating pharmaceutical development from R&D through commercial GMP production.
Yaohai Bio-Pharma, a leader in microbial-based CRDMO services, is pleased to announce its participation in CPHI Frankfurt 2025, the premier global event for pharmaceutical supply chain innovation. The event will take place at Messe Frankfurt, Germany, from October 28 to 30, 2025.
Visit Yaohai Bio-Pharma at Booth #41D65 to discover our end-to-end CRDMO solutions accelerating drug development from early R&D through commercial production. Leverage our proven expertise in microbial expression systems across:
• Recombinant proteins & peptides
• Nucleic acid therapeutics
• Nanobodies
• Plasmid DNA
• Innovative vaccines
About CPHI Frankfurt:
CPHI Frankfurt gathers tens of thousands of global pharmaceutical professionals across the entire supply chain – from drug development and manufacturing to outsourcing services and technology innovation. As the industry’s most influential gathering, it serves as an essential platform for networking, business development, and cutting-edge biologic industry insights.
About Yaohai Bio-Pharma:
Yaohai Bio-Pharma is a CRDMO with over a decade of experience in microbial expression systems. Focused on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and novel vaccines, Yaohai provides full-lifecycle solutions from R&D to commercial manufacturing. The company is committed to building an open and integrated CRO/CDMO/MAH platform that drives innovation from discovery to commercialization, serving as a trusted partner to global biopharma companies.
